Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection-Reference-Cited by-同舟云学术

Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection

Published:2007 Issue:5 Volume:57 Page:756-761
ISSN:0004-3591
Container-title:Arthritis & Rheumatism
language:en
Short-container-title:Arthritis Rheum

Author:

Gómez-Reino Juan J.,Carmona Loreto,Ángel Descalzo Miguel,

Publisher

Wiley

Subject

Pharmacology (medical),Immunology,Rheumatology,Immunology and Allergy

Reference22 articles.

1. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active-surveillance report

2. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists

3. EuroTB, and the WHO Collaborating Centre for the Surveillance of Tuberculosis in Europe. Surveillance of tuberculosis in Europe: report on tuberculosis cases notified in 2004. Saint-Maurice (France): Institut de Veille Sanitaire; 2006. URL: http://www.eurotb.org/rapports/2004/eurotb_report_2004.pdf.

Cited by 352 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tuberculin skin test repetition after TNF-α inhibitors in patients with chronic inflammatory arthritis: a long-term retrospective cohort in endemic area;Advances in Rheumatology;2024-09-13

2. (Re-)introduction of TNF antagonists and JAK inhibitors in patients with previous tuberculosis: a systematic review;Clinical Microbiology and Infection;2024-08

3. The risk of tuberculosis infection in Saudi patients receiving adalimumab, etanercept, and tocilizumab therapy;Journal of Infection and Public Health;2024-06

4. Management of postinfectious inflammatory arthritis;Current Opinion in Rheumatology;2024-02-22

5. Analysis of Risk Factors for Developing Tuberculosis in Patients Who Received Prophylactic Latent Tuberculosis Infection Treatment with Experience of Biologic Medications;Biological and Pharmaceutical Bulletin;2023-12-01